Literature DB >> 7533835

Molecular weight dependent tissue accumulation of dextrans: in vivo studies in rats.

R Mehvar1, M A Robinson, J M Reynolds.   

Abstract

The effects of molecular weight (M(r)) on the serum and urine pharmacokinetics and tissue distribution of dextrans, potential macromolecular carriers for drug delivery, were studied in rats. A single 5 mg/kg dose of fluorescein-labeled dextrans (FDs) with a M(r) of 4000 (FD-4), 20,000 (FD-20), 70,000 (FD-70), or 150,000 (FD-150) was administered into the tail vein of separate groups of rats. At different times after the administration of each FD, animals were sacrificed, and blood, urine, and various tissues were obtained. The concentrations of FDs in the samples were subsequently determined by using a sensitive and specific high performance size exclusions chromatographic method. Among the tissues studied, high accumulation of dextrans was found only in the liver (liver:serum AUC ratios < or = 29) and spleen (spleen:serum AUC ratios < or = 10), with high concentrations in these tissues persisting even at the last sampling time (96 h). In contrast, the serum concentrations of the studied FDs were not measurable beyond 12 h. The serum and urine kinetics and the liver, spleen, and kidney accumulation of FDs demonstrated a significant degree of M(r) dependency. The total and renal clearance of FDs consistently decreased with an increase in M(r). However, the effects of M(r) on the tissue accumulation of dextrans was tissue dependent. For the liver, the tissue:serum AUC ratios increased from 0.346 for FD-4 to 15.2 for FD-20 and 28.8 for FD-70, while a further increase in M(r) to 150 kDa (FD-150) resulted in lowering the ratio to 8.59 in this tissue. For the spleen, the ratios increased from 0.095 for FD-4 to 9.56 for FD-150.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7533835     DOI: 10.1002/jps.2600831024

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  20 in total

1.  Intracellular Distribution-based Anticancer Drug Targeting: Exploiting a Lysosomal Acidification Defect Associated with Cancer Cells.

Authors:  Rosemary A Ndolo; Damon T Jacobs; M Laird Forrest; Jeffrey P Krise
Journal:  Mol Cell Pharmacol       Date:  2010

2.  Synthesis and in vitro characterization of novel dextran-methylprednisolone conjugates with peptide linkers: effects of linker length on hydrolytic and enzymatic release of methylprednisolone and its peptidyl intermediates.

Authors:  Suman Penugonda; Anil Kumar; Hitesh K Agarwal; Keykavous Parang; Reza Mehvar
Journal:  J Pharm Sci       Date:  2008-07       Impact factor: 3.534

3.  Fluorochrome-functionalized nanoparticles for imaging DNA in biological systems.

Authors:  Hoonsung Cho; David Alcantara; Hushan Yuan; Rahul A Sheth; Howard H Chen; Peng Huang; Sean B Andersson; David E Sosnovik; Umar Mahmood; Lee Josephson
Journal:  ACS Nano       Date:  2013-02-07       Impact factor: 15.881

4.  Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: immunosuppressive effects after in vivo administration to rats.

Authors:  R Mehvar; D A Hoganson
Journal:  Pharm Res       Date:  2000-11       Impact factor: 4.200

5.  Pharmacokinetic and Tissue Distribution of Orally Administered Cyclosporine A-Loaded poly(ethylene oxide)-block-Poly(ε-caprolactone) Micelles versus Sandimmune® in Rats.

Authors:  Ziyad Binkhathlan; Raisuddin Ali; Wajhul Qamar; Hanan Al-Lawati; Afsaneh Lavasanifar
Journal:  Pharm Res       Date:  2021-02-08       Impact factor: 4.200

6.  Evaluation of glycodendron and synthetically modified dextran clearing agents for multistep targeting of radioisotopes for molecular imaging and radioimmunotherapy.

Authors:  Sarah M Cheal; Barney Yoo; Sarah Boughdad; Blesida Punzalan; Guangbin Yang; Anna Dilhas; Geralda Torchon; Jun Pu; Don B Axworthy; Pat Zanzonico; Ouathek Ouerfelli; Steven M Larson
Journal:  Mol Pharm       Date:  2013-11-23       Impact factor: 4.939

7.  The role of lysosomes in limiting drug toxicity in mice.

Authors:  Rosemary A Ndolo; M Laird Forrest; Jeffrey P Krise
Journal:  J Pharmacol Exp Ther       Date:  2010-01-07       Impact factor: 4.030

8.  Plasma pharmacokinetics and tissue disposition of novel dextran-methylprednisolone conjugates with peptide linkers in rats.

Authors:  Suman Penugonda; Hitesh K Agarwal; Keykavous Parang; Reza Mehvar
Journal:  J Pharm Sci       Date:  2010-03       Impact factor: 3.534

9.  Attenuation of acute rejection in a rat liver transplantation model by a liver-targeted dextran prodrug of methylprednisolone.

Authors:  Anjaneya P Chimalakonda; Donald L Montgomery; Jon A Weidanz; Imam H Shaik; Justin H Nguyen; John J Lemasters; Eiji Kobayashi; Reza Mehvar
Journal:  Transplantation       Date:  2006-03-15       Impact factor: 4.939

10.  Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: local immunosuppressive effects in liver after systemic administration to rats.

Authors:  Anjaneya P Chimalakonda; Reza Mehvar
Journal:  Pharm Res       Date:  2003-02       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.